ACA
ANIX icon

Aptus Capital Advisors’s Anixa Biosciences ANIX Stock Holding History

Aptus Capital Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Buy
+10,885
New +$30.3K ﹤0.01% 1451

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Aptus Capital Advisors's ANIX Position: Q2 2026 in Review

Aptus Capital Advisors opened a new position in Anixa Biosciences (ANIX) in Q2 2026: 10,885 shares worth $30.5K. The stake represents ﹤0.01% of the portfolio and ranks #1451 among its holdings.

62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Aptus Capital Advisors held 10,885 shares of Anixa Biosciences worth $30.5K as of Q2 2026.
  • Anixa Biosciences was a new Aptus Capital Advisors position in Q2 2026.
  • Anixa Biosciences made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1451 holding.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.